- Home
- ASPI vs PSNL Comparison
ASPI vs PSNL Comparison
Compare ASPI & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASPI | PSNL |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.5M | 729.1M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ASPI | PSNL |
|---|---|---|
| Price | $5.13 | $6.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $12.00 | ★ $12.20 |
| AVG Volume (30 Days) | ★ 4.4M | 1.4M |
| Earning Date | 04-10-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | N/A | ★ N/A |
| Revenue | $23,849,000.00 | ★ $69,648,000.00 |
| Revenue This Year | $82.23 | $15.47 |
| Revenue Next Year | $126.49 | $39.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $3.92 | $3.09 |
| 52 Week High | $14.49 | $11.50 |
Technical Indicators
Market Signals| Indicator | ASPI | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 45.54 |
| Support Level | $3.98 | $5.81 |
| Resistance Level | $6.65 | $6.94 |
| Average True Range (ATR) | 0.41 | 0.49 |
| MACD | 0.15 | 0.08 |
| Stochastic Oscillator | 65.68 | 55.96 |
Price Performance
Historical ComparisonAbout ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.